Attention Deficit Hyperactivity Disorder (ADHD) Drugs Market by Product and Geography - Forecast and Analysis 2021-2025

The attention deficit hyperactivity disorder (ADHD) drugs market share is expected to increase by USD 9.61 billion from 2020 to 2025, and the market's growth momentum will accelerate at a CAGR of 9.06%.

This attention deficit hyperactivity disorder drugs market research report provides valuable insights on the post COVID-19 impact on the market, which will help companies evaluate their business approaches. Furthermore, this report extensively covers attention deficit hyperactivity disorder drugs market segmentation by product (stimulants and non-stimulants) and geography (North America, Europe, Asia, and ROW). The attention deficit hyperactivity disorder drugs market report also offers information on several market vendors, including Aurobindo Pharma Ltd., Aytu BioPharma Inc., Eli Lilly and Co., Glenmark Pharmaceuticals Ltd., Johnson and Johnson Inc., Novartis AG, Purdue Pharma LP, SHIONOGI Co. Ltd., Takeda Pharmaceutical Co. Ltd., and Tris Pharma Inc. among others.

What will the Attention Deficit Hyperactivity Disorder Drugs Market Size be During the Forecast Period?

Download the Free Report Sample to Unlock the Attention Deficit Hyperactivity Disorder Drugs Market Size for the Forecast Period and Other Important Statistics

 

Attention Deficit Hyperactivity Disorder Drugs Market: Key Drivers and Challenges

The rising government support is notably driving the ADHD drugs market growth, although factors such as lack of proper diagnostic criteria for ADHD in adults may impede market growth. Our research analysts have studied the historical data and deduced the key market drivers and the COVID-19 pandemic impact on the attention deficit hyperactivity disorder drugs industry. The holistic analysis of the drivers will help in deducing end goals and refining marketing strategies to gain a competitive edge.

Key Attention Deficit Hyperactivity Disorder Drugs Market Driver

The global ADHD drugs market is currently witnessing an increase in the number of government initiatives to promote awareness of the disease and to fund drug development in the area of mental health therapeutics. For instance, the US Department of Health and Human Services (HHS) donated $3,454 million to the Substance Abuse and Mental Health Services Administration (SAMHSA) to address the needs of people with mental illnesses. Similarly, the National Health Service (NHS) England has set up a plan to help people with mental illness. The NHS England spent approximately $16 billion on mental health in 2018-2020. Additionally, the CDC funds the National Resource Center (NRC) on ADHD, a program designed to help children and adults with ADHD. The NRC program provides information, resources, and advice to parents on how to help their children with ADHD. Thus, the rising government support to help people with ADHD is expected to drive the growth of the market during the forecast period. 

Key Attention Deficit Hyperactivity Disorder Drugs Market Challenge

Physicians currently face a daunting challenge in terms of the diagnosis of ADHD in adults. The current diagnostic criteria for ADHD include the presence of 18 symptoms, which are broadly categorized under three main symptoms, namely, inattention, impulsivity, and hyperactivity. Clinical studies have revealed that these symptoms play a steering role in defining ADHD in both children and adults of any age. However, to validate these symptoms in adults, physicians need to perform a longitudinal study of their childhood, family history, treatment response, and neuropsychological analysis. The use of screening tools and informed applications such as DSM-IV, brochures, and the cultivation of consultation and referral services can help physicians significantly augment the diagnosis and treatment of adults with ADHD. However, until a proper guideline is laid for the diagnosis of ADHD in adults, the consumption of ADHD drugs will be limited, which will hinder the growth of the market, both in terms of volume and value, during the forecast period.

This attention deficit hyperactivity disorder drugs market analysis report also provides detailed information on other upcoming trends and challenges that will have a far-reaching effect on the market growth. The actionable insights on the trends and challenges will help companies evaluate and develop growth strategies for 2021-2025.

Who are the Major Attention Deficit Hyperactivity Disorder Drugs Market Vendors?

The report analyzes the market's competitive landscape and offers information on several market vendors, including:

 

• Aurobindo Pharma Ltd.
• Aytu BioPharma Inc.
• Eli Lilly and Co.
• Glenmark Pharmaceuticals Ltd.
• Johnson and Johnson Inc.
• Novartis AG
• Purdue Pharma LP
• SHIONOGI Co. Ltd.
• Takeda Pharmaceutical Co. Ltd.
• Tris Pharma Inc.

 

This statistical study of the attention deficit hyperactivity disorder drugs market encompasses successful business strategies deployed by the key vendors. The ADHD drugs market is fragmented and the vendors are deploying various organic and inorganic growth strategies to compete in the market.

To make the most of the opportunities and recover from post COVID-19 impact, market vendors should focus more on the growth prospects in the fast-growing segments, while maintaining their positions in the slow-growing segments.

The attention deficit hyperactivity disorder drugs market forecast report offers in-depth insights into key vendor profiles. The profiles include information on the production, sustainability, and prospects of the leading companies. 

Which are the Key Regions for Attention Deficit Hyperactivity Disorder Drugs Market?

For more insights on the market share of various regions Request for a FREE sample now!

40% of the market's growth will originate from North America during the forecast period. The US and Canada are the key markets for attention deficit hyperactivity disorder drugs in North America. However, the market growth rate in this region will be slower than the growth of the market in Asia and Europe.

The rise in the attentiveness of parents toward children with ADHD, approval & commercialization of drugs, and increase in the number of clinical trials will facilitate the attention deficit hyperactivity disorder drugs market growth in North America over the forecast period. This market research report entails detailed information on the competitive intelligence, marketing gaps, and regional opportunities in store for vendors, which will assist in creating efficient business plans.

What are the Revenue-generating Product Segments in the Attention Deficit Hyperactivity Disorder Drugs Market?

To gain further insights on the market contribution of various segments Request for a FREE sample

The attention deficit hyperactivity disorder drugs market share growth by the stimulants segment will be significant during the forecast period. Stimulants are approved by the US FDA for use in children and adults and are considered gold standards for the treatment of ADHD. Considering the vast use of stimulants in the ADHD therapeutic area, the market is expected to witness rapid growth during the forecast period.

This report provides an accurate prediction of the contribution of all the segments to the growth of the ADHD drugs market size and actionable market insights on post COVID-19 impact on each segment.

 

Attention Deficit Hyperactivity Disorder Drugs Market Scope
Report Coverage	Details
Page number	120
Base year	2020
Forecast period	2021-2025
Growth momentum & CAGR	Accelerate at a CAGR of 9.06%
Market growth 2021-2025	$ 9.61 billion
Market structure	Fragmented
YoY growth (%)	6.44
Regional analysis	North America, Europe, Asia, and ROW
Performing market contribution	North America at 40%
Key consumer countries	US, Canada, Germany, China, and UK
Competitive landscape	Leading companies, Competitive strategies, Consumer engagement scope
Key companies profiled	Aurobindo Pharma Ltd., Aytu BioPharma Inc., Eli Lilly and Co., Glenmark Pharmaceuticals Ltd., Johnson and Johnson Inc., Novartis AG, Purdue Pharma LP, SHIONOGI Co. Ltd., Takeda Pharmaceutical Co. Ltd., and Tris Pharma Inc.
Market dynamics	Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, Market condition analysis for the forecast period
Customization purview	If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized.

Request for a FREE sample

What are the Key Data Covered in this Attention Deficit Hyperactivity Disorder Drugs Market Report?

• CAGR of the market during the forecast period 2021-2025
• Detailed information on factors that will drive attention deficit hyperactivity disorder drugs market growth during the next five years
• Precise estimation of the attention deficit hyperactivity disorder drugs market size and its contribution to the parent market
• Accurate predictions on upcoming trends and changes in consumer behavior
• The growth of the ADHD drugs industry across North America, Europe, Asia, and ROW
• A thorough analysis of the market's competitive landscape and detailed information on vendors
• Comprehensive details of factors that will challenge the growth of ADHD drugs market vendors

We can help! Our analysts can customize this report to meet your requirements. Get in touch